| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
B in
myocardial reperfusion and reduces reperfusion injury
Departments of 1 Medicine and 2 Pathology and Laboratory Medicine, 3 Division of Laboratory Animal Medicine, 4 Lineberger Comprehensive Cancer Center, 5 Department of Biology and Curriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, North Carolina 27516; and 6 Millennium Pharmaceuticals, Cambridge, Massachusetts 02139
 |
ABSTRACT |
|---|
 TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Both acute
coronary occlusion and reperfusion of an infarct-related artery
lead to significant myocardial cell death. Recent evidence has been
presented that activation of the transcription factor nuclear
factor-
B (NF-B) plays a critical role in reperfusion injury.
NF-B is usually bound to its inhibitor, IB, and classic activation of NF-B occurs when the 20S proteasome degrades IB that has been phosphorylated and ubiquitinated. In this study, activation of NF-B was inhibited by systemic administration of a 20S
proteasome inhibitor (PS-519) in a porcine model of myocardial reperfusion injury. The experimental protocol induced myocardial ischemia in the distribution of the left anterior descending
coronary artery for 1 h with subsequent reperfusion for 3 h.
A single systemic treatment with PS-519 reduced 20S proteasome
activity; blocked activation of NF-B induced by reperfusion; reduced
creatine kinase, creatine kinase-muscle-brain fraction, and troponin I
release from the myocardium; preserved regional myocardial function
measured by segmental shortening; significantly reduced the size of
myocardial infarction; and exhibited no acute toxicity. These data show
that myocardial reperfusion injury can be inhibited by using proteasome inhibitors, which likely function through the inhibition of NF-B activation.
inflammation; myocardial contraction; multienzyme complexes; transcription factors
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
REPERFUSION INJURY is a complex set of events that paradoxically increases tissue injury when oxygenated blood is supplied to ischemic tissues (1, 2, 6, 26). Myocardial infarction (MI) develops largely as a result of damage to ischemic and reperfused cardiac myocytes and endothelial cells. Current therapy for MI can achieve rapid and efficient reperfusion of the occluded or infarct-related coronary artery using thrombolytic treatment or direct coronary artery angioplasty. However, there is no generally accepted treatment or therapeutic intervention for the attendant reperfusion injury, which, if minimized or halted, would likely result in improved ventricular function, the major determinant of long-term survival in humans (6, 26).
Several lines of evidence suggest that a major pathway in reperfusion
injury is mediated by activation of nuclear factor-B (NF-B).
NF-B is a dimer of members of the Rel family of proteins. The
classic form of NF-B is composed of p50 (NF-B1) and p65 (RelA)
(4, 16). In most cells, NF-B is inactive and
sequestered in the cytoplasm due to binding by an inhibitor protein
(IB). During activation of NF-B, IB is phosphorylated by the
IB kinase complex (37), targeting it for ubiquitination
and degradation by the proteasome. The unbound NF-B is transported
to the nucleus where it binds to specific promotor sequences and
regulates gene expression, including those involved in the inflammation
and likely reperfusion injury (3, 16, 32). Importantly,
proteasome inhibitors have been shown to inhibit IB degradation and
block NF-B nuclear translocation (2, 15).
In this study, we addressed the hypothesis that inhibiting proteasome
activity would reduce reperfusion injury in the in situ heart by a
mechanism that involved inhibition of activation of inducible NF-B.
The proteasome inhibitor PS-519 (2) was shown to
significantly reduce proteasome activity in circulating leukocytes. Also, with the use of a 1-h ischemia protocol followed by a 3-h reperfusion protocol, PS-519 was shown to block activation of myocardial NF-B by electromobility shift assay (EMSA); to reduce myocardial serum creatine kinase (CK), CK muscle-brain fraction (CK-MB), and troponin I (TnI) release; to preserve regional myocardial function measured by segmental shortening; to reduce the area of MI;
and to exhibit no acute toxicity. Our data support the hypothesis that proteasome inhibition reduces reperfusion injury in an
experimental model of MI by a mechanism that involves inhibition of
activation of NF-B. These data provide proof of the concept for
considering the therapeutic potential of proteasome inhibitors in
humans following reperfusion of an infarct-related coronary artery.
| |
MATERIALS AND METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Experimental Animals
Male and female pigs (Sus scrofa) between 6 and 8 mo of age were used. All pigs were bred and raised at the Francis Owen Blood Research Laboratory at the University of North Carolina, Chapel Hill. All animals were treated according to the standards set in the Guide for the Care and Use of Laboratory Animals [National Institutes of Health (NIH) Publication No. 85-23]. All procedures were in accordance with institutional guidelines under approved protocols at the University of North Carolina.Myocardial Ischemia, Infarction, Reperfusion, and PS-519 Treatment Protocols in Pigs
The pigs were anesthetized with ketamine (10 mg/kg im), intubated, and maintained with isofluorane (2-4% in air supplemented with 1 l/min oxygen). A median sternotomy was performed, and the pigs were placed on positive pressure ventilation. Arterial blood gases were monitored, and the ventilator was adjusted to maintain pH 7.35-7.45, PCO2 35-45 mmHg, and PO2 >100 mmHg.The left anterior descending coronary artery (LAD) was dissected free of surrounding tissues at two sites, and an encircling suture was placed proximally and a Doppler flow velocity crystal distally. Measurements of coronary blood flow (CBF) velocity were performed in vivo using a custom-made Doppler system (Dr. Craig J. Hartley, Baylor College of Medicine, Houston, TX). CBF was also confirmed by injecting contrast media in the left main coronary artery under fluoroscopic guidance. A Simmons catheter (SIMI/II, Cook; Bloomington, IN) was placed in the coronary sinus for cardiac venous sampling (12). An eight-channel strip-chart oscillograph (Linearcorder WR3310, Western Graphtec; Irvine, CA) was used to monitor and record CBF velocity, blood pressure via a Millar catheter, and heart rate by electrocardiogram. Body temperature was monitored by thermometers via both rectal and myocardial temperature probes and maintained at temperatures of 36 to 38°C with warming blankets (TP-500, Gaymar; Orchard Park, NY).
PS-519 (1 mg/kg, Millennium Pharmaceuticals; Cambridge, MA) was dissolved in an excipient consisting of an equal volume of propylene glycol (1,2-propanediol, P-1009, Sigma Chemical; St. Louis, MO) and sterile saline (0.9% NaCl, 2F7124, Baxter Healthcare; Deerfield, IL). PS-519 dissolved in excipient (PS-519-treated group) or excipient alone (control group) was administered over ~1-3 min via a coronary angiography catheter in a supraaortic valvular region immediately after baseline samples were taken and just before LAD occlusion.
The LAD was then occluded for 1 h to produce an anterior MI and
subsequently reopened and allowed to reperfuse for 3 h. Occlusion and reperfusion were verified by changes in Doppler flow velocity signals and by angiographic visualization. Myocardial biopsies of
ischemic and nonischemic myocardium were obtained by
using a myocardial bioptome (T-Rex, Boston Scientific SciMed; Maple Grove, MN). Blood samples for serum CK, CK-MB, TnI, and white blood
cell (WBC) 20S proteasome activity analysis were taken from the
coronary sinus (see Leukocyte Isolation and 20S Proteasome Activity Analysis and Measurement of Serum K, CK-MB, and TnI
Levels). Biopsy and blood samples were taken at time
points indicated on Table 1. The
experiment was concluded with administration of an overdose of
pentobarbital sodium (6 grains/4.5 kg iv) The hearts were then removed
and processed for quantification of the area of MI as detailed below.
|
Myocardial Segment Shortening Analysis
Myocardial segment shortening was analyzed in ischemic and nonischemic myocardium in four control and four PS-519-treated pigs. Subepicardial, multidirectional ultrasonic 0.7-mm dimension crystals (Sonometrics; Ontario, Canada) were implanted 10 mm apart in the minor axis plane to subtend the myocardial region supplied by the LAD and to measure longitudinal segment length shortening with high-frequency sampling (>100 Hz) (8). Segmental shortening in the ischemic and nonischemic regions was compared, at the indicated time points (Table 1), using Sonosoft sonomicrometer analysis software (version 3.1.0, Sonometrics).Leukocyte Isolation and 20S Proteasome Activity Analysis
Leukocyte isolation.
WBCs were isolated from heparinized venous blood using Nycoprep 1.077 (Nycomed; Oslo, Norway) according to the manufacturer's recommendations with modifications: the leukocytes were isolated by
centrifugation (800 g for 30 min at room temperature),
washed in 1× phosphate-buffered saline, recentrifuged (400 g for 10 min), and stored at 
80°C.
Fluorometric 20S proteasome activity analysis.
The prepared WBCs were lysed with EDTA (5 mmol/l, pH 8.0) by incubation
for 1 h and then centrifuged (6,600 g, 10 min, 4°C). Lysed cells were then resuspended in buffer (1 mol/l dithiothreitol and
1 mol/l HEPES), centrifuged (2,200 g, 15 min, 4°C), and
then mixed with substrate buffer (20 mmol/l HEPES, 0.5 mmol/l EDTA, and
0.35% SDS) and 60 µmol/l Ys substrate
(succinyl-Leu-Leu-Val-Tyr-amido-4-methyl-coumarin, Bachem; Bubendorf,
Switzerland) at pH 8.0 and 37°C. The rate of substrate cleavage per
20S proteasome activity was determined (expressed as pmol
AMC · s
1 · mg
protein1, where AMC is 7-amino-4-methylcoumarin).
Measurement of Serum CK, CK-MB, and TnI Levels
Serum for CK, CK-MB, and TnI analysis was prepared from blood by centrifugation separation in SST Gel and Clot Activator Vacutainers (Becton Dickinson; Franklin Lakes, NJ). Total CK was measured by an enzymatic method using a Vitros 950 chemical analyzer (Johnson & Johnson Clinical Diagnostics; Rochester, NY) according to the manufacturer's recommendations. CK-MB and TnI were measured by a microparticle enzyme immunoassay method using an Axsym chemical analyzer (Abbot; Abbot Park, IL) according to the manufacturer's recommendations.Nuclear Extractions and EMSA for NF-B
-32P-labeled double-stranded DNA
probe (~2.5 ng) containing a B site from the class I major
histocompatibility complex promoter or a constitutive nuclear protein
(Oct-1, sc-232, Santa Cruz Biotechnology; Santa Cruz, CA) to control
for protein loading and separated by EMSA as described (10,
18)
Quantification of Area at Risk and Myocardial Infarction
Area at risk. After the 3 h of reperfusion, the LAD was reoccluded, and 20 ml of a freshly made solution of 20% thioflavin-S (T-1892, Sigma-Aldrich; St. Louis, MO) in sterile saline (0.9% NaCl, 2F7124, Baxter Healthcare) were injected into the aortic valve sinuses adjacent to the ostia of the coronary arteries with fluoroscopic guidance immediately after administration of the pentobarbitol overdose and just before cessation of the heartbeat. A cardiectomy was performed, and the heart was cut from apex to base into seven serial sections of ~10 mm thickness. The myocardial sections were then placed on a light box mounted with a digital camera (Q-mini, Konica Photo Imaging; Englewood Cliffs, NJ), fitted with a polarizer, and illuminated by an ultraviolet lamp (UVP systems; Upland, CA). Myocardial sections were photographed in plane alongside a metric ruler for subsequent calibration of the computer-assisted measurements of the surface area. Thioflavin S is fluorescent under ultraviolet light in perfused tissue. Myocardium that did fluoresce was defined as thioflavin positive and therefore as nonischemic. Myocardium that did not fluoresce was defined as thioflavin negative and therefore as ischemic (21, 22). The area of the ischemic tissue was defined as the ischemic area at risk (AAR).
Myocardial infarction. After fluorescent thioflavin imaging, the sections were incubated at room temperature in 500 ml of a freshly made solution of 1% triphenyltetrazolium chloride (TTC, T-8877, Sigma-Aldrich) for 15 min. The sections were then photographed with the same camera system but under incandescent illumination. TTC forms a red precipitate in viable tissue, and myocardium that stained red was defined as TTC positive and therefore as viable. Myocardium that did not stain red appeared pale yellow under incandescent light and was defined as TTC negative and therefore as infarcted myocardium (35). The area of infarcted tissue was defined as the area of MI. On completion of imaging, the sections were fixed in 10% buffered formalin.
Quantification of MI and AAR With Computer-Assisted Planimetry
Images were downloaded from the digital camera into Adobe PhotoShop 5.5 (Adobe Systems; Seattle, WA), and the area of MI and AAR were determined using NIH Image 1.61 (Bethesda, MD). Each digital image was individually calibrated for area before measurements were taken. The following three surface areas were measured: TTC-positive (viable) myocardium, thioflavin S-positive (perfused) myocardium, and total myocardium. The following formulas were then applied to the measurements: 1) area of MI = total myocardial section area TTC-positive myocardium; 2) percent area of
MI = area of MI 
total myocardial section area × 100;
3) AAR = total myocardial section area thioflavin-positive myocardium; 4) percent AAR = AAR total myocardial section area × 100; 5)
nonischemic myocardium = total myocardial section
area AAR; and 6) percent nonischemic myocardium = nonischemic myocardium total
myocardial section area × 100.
Detection of Apoptosis in Reperfused Sections of Entire Myocardium
Cross sections of the entire heart from control and PS-519-treated pigs were prepared by immersion fixation for 30 min in 10% buffered formalin followed by a change to fresh fixative and immersion for an additional 24 h. The fixed tissues were paraffin embedded, and 5-µm sections were mounted on ProbeOn Plus slides (15-188-52, Fisher Scientific; Pittsburgh, PA). Myocardial cells exhibiting apoptosis were detected by the terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) immunohistochemistry method using a Trevigen Apoptotic Cell system (TACS) Blue Label reaction (CardioTACS apoptosis kit, 4827-30-K, Trevigen; Gaithersburg, MD). This system was used according to the manufacturer's recommendations, with modifications made to the quenching and incubation times that optimized detection of positive cells using controls. Positive controls were prepared by digestion of myocardial sections with TACS-Nuclease in appropriate buffer for 60 min at 37°C. Negative controls were by incubation with buffer only.Statistical Methods
The data for proteasome activity, coronary sinus CK, area of MI, AAR, and area of nonischemic myocardium are described as means ± SD. The exact Wilcoxon test was used for comparisons between PS-519-treated and control groups. P values <0.05 were considered statistically significant.| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Myocardial Reperfusion Injury in Pigs
Twenty-eight pigs were entered into these experiments. Control animals (n = 13) were given excipient alone, whereas PS-519-treated animals (n = 15) were given excipient with a single dose of PS-519 as described in MATERIALS AND METHODS. Six pigs, two control and four PS-519 treated, did not complete the protocol because of irreversible ventricular fibrillation during the ischemia and reperfusion protocol and were excluded from analysis. The total number of pigs is too small to determine whether these arrthymias were due to drug toxicity or the large percentage of the left ventricular being ischemic (see Table 5). Two PS-519-treated pigs did not complete the protocol because of failure to reperfuse completely and were also excluded. In summary, 11 control and 9 PS-519-treated pigs completed the protocol. There was no significant difference in heart rate and blood pressure between the two groups (data not shown).PS-519 Inhibits 20S Proteasome Activity
PS-519 significantly reduced the proteasome activity in circulating WBCs from 16.67 to 1.11 pmol AMC · s1 · mg
protein1 (Table 2). The
control group had no significant change in WBC proteasome activity with
the administration of excipient (Table 2). Pre-PS-519-treated
proteasome activity observed in all animals was comparable (Table 2).
These results demonstrate that PS-519 is very effective at inhibiting
proteasome activity in pigs as previously reported in rats
(9). Inhibition of 20S proteasome activity in WBCs closely
correlated with the inhibition found in other tissues including the
myocardium (data not shown).
|
An additional pig was given PS-519 at 1.0 mg/kg intravenously and
then monitored for several weeks without MI. Proteasome activity
decreased 93% (11.5 to 0.8 pmol
AMC · s1 · mg
protein1) within 30 min of administration and returned to
50% of baseline (5.7 pmol
AMC · s1 · mg
protein1) at 24 h. Importantly, no clinical toxicity
was detected during the recovery period.
PS-519 Preserves Regional Myocardial Function as Measured by Segmental Shortening
Ultrasonic sonomicrometer measurements of longitudinal myocardial segmental shortening were taken in four control and four PS-519-treated pigs to determine whether PS-519 preserved regional myocardial function. Baseline-adjusted measurements were calculated by taking the absolute distance of segmental shortening at baseline, defining that as 100%, and then reporting the relative change in the distance of segmental shortening at later time points. In the ischemic region, baseline-adjusted segmental shortening was significantly greater in the PS-519-treated pigs compared with the control pigs at both 1 h of ischemia (102 ± 22% vs. 47 ± 17%) and at 3 h of reperfusion (63 ± 23% vs. 32 ± 13%, P < 0.05) (Table 3). In the nonischemic region, baseline-adjusted segmental shortening was not significantly different between control and PS-519-treated pigs during the experiment (data not shown).
|
NF-B Is Activated by Reperfusion and Is Inhibited by PS-519
B
binding activity by EMSA to determine whether PS-519 was effective at
inhibiting NF-B activation and to determine whether ischemia
and/or reperfusion induced activation of NF-B in vivo. Activated
NF-B was not detected during ischemia but was consistently detected in the myocardium of the control animals following 1 h of
reperfusion (Fig. 1, A vs.
B). Importantly, activated
NF-B was not detected after ischemia and reperfusion
in the myocardium of the PS-519-treated animals. Differences
between control and PS-519-treated groups cannot be accounted for by
differences in loading of nuclear extracts as evidenced by EMSA
performed using a constitutive octamer probe to detect Oct-1 DNA
binding activity (Fig. 1, C and D), although it
is noted that there is some variability of binding of Oct-1 in these
experiments.
|
PS-519 Blocks Increase of Serum CK, CK-MB, and TnI Levels
CK and TnI release from the damaged myocardium are clinically accepted measures of myocardial cell death (11). Baseline-adjusted CK levels observed in the PS-519-treated animals were 17% less relative to the control animals after 1 h of ischemia. Baseline-adjusted CK, CK-MB, and TnI levels were ~47%, 67%, and 76% less, respectively, at 3 h of reperfusion (Table 4). Baseline-adjusted values were calculated by subtracting each pig's initial serum value from all subsequent values to express net change in levels that occurred during the experiment. The difference in the two groups is not significant because of the wide variation in values, which is typical of these experiments. However, the marked reduction in mean CK, CK-MB, and TnI release in PS-519-treated animals strongly suggests that the difference was a direct effect of administration of this proteasome inhibitor.
|
PS-519 Reduces Area of MI and AAR
Consistent with the ability of PS-519 to block NF-B activation and to reduce serum CK levels, there were
significant reductions in the area of MI and the area of MI relative to
the AAR for the PS-519-treated animals (89.7% and 90.4% reductions,
P < 0.05 and 0.03, respectively, Table
5 and Fig.
2). The AAR for the heart sections distal
to the LAD occlusion were not significantly different between the
PS-519-treated and control animals (55.9% and 44.8%, P = not significant, respectively, Table 5 and Fig. 2).
The area of MI and AAR were measured in 9 of 9 PS-519-treated and 9 of 11 control animals because two sets of control group images were lost
during processing. Importantly, all 9 control pigs had a TTC-positive
area consistent with an MI, whereas only 1 of 9 treated pigs had a
detectable TTC-positive area. These data indicate that a single dose of
the proteasome inhibitor PS-519 can reduce myocardial injury during
3 h of reperfusion.
|
|
Apoptosis Was Not Detected in Control or PS-519-Treated Pig Hearts
The number of cells undergoing apoptosis as judged by TUNEL staining was <0.01% in both the infarct and noninfarct zones, and the difference between PS-519-treated and control tissues was not significant. Positive controls exhibited >95% of cells having positive TUNEL staining, and negative controls exhibited <0.01% (data not shown).| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
In this MI and reperfusion model, treatment with PS-519
significantly reduced 20S proteasome activity in circulating
leukocytes, markedly reduced release of CK, CK-MB, and TnI from the
myocardium, inhibited activation of inducible NF-B in
ischemic and reperfused myocardium, preserved regional
myocardial function measured by segmental shortening, and reduced the
area of MI. Taken together, these data demonstrate that proteasome
inhibition by treatment with PS-519 significantly reduces myocardial
reperfusion injury in an open-chest porcine model by a mechanism that
apparently includes inhibition of activation of NF-B.
Prior studies have shown that inhibition of inducible NF-B
activation affects myocardial reperfusion injury. In one study, double-stranded DNA oligonucleotides were transfected into rat myocardium in vivo using the hemagglutinating virus of Japan (HVJ) liposome (27). Both a reduction in activation of inducible
NF-B and reduced myocardial reperfusion injury were seen. Compared with this method, our ability to easily solubilize and administer PS-519 and monitor its effect on proteasome activity in circulating WBC
make it a potentially more attractive pharmacological agent than one
that requires transfection reagents. Another study used PS-519 in an ex
vivo Langendorff rat heart preparation perfused with plasma and WBCs
(9). Myocardial reperfusion injury mediated by WBCs was
markedly reduced. In a mouse model of acute pancreatitis and myocardial
infarction, proteasome inhibition resulted in a smaller infarct
compared with controls (15). Our study utilized a
different and larger species in which the heart was perfused with whole
blood under systemic pressure and showed inhibition of NF-B in the
reperfused myocardium by EMSA; reduction of myocardial CK, CK-MB, and
TnI release; preservation of regional myocardial function measured by
segmental shortening; and reduction in the area of MI. Other prior
studies using pig models have investigated MI following 45-90 min
of ischemia and 2-24 h of reperfusion. Our study used
1 h of ischemia followed by 3 h of reperfusion, and
the AAR and AAR infarcted observed in our control pigs fall within the
range of these previously published results (14, 19, 20, 23, 29,
30, 33). Our model is relevant to human disease where myocardial
damage is sustained within minutes to hours following heart attack.
Considered together, our data then confirm and extend those previous
studies with a unique therapeutic agent that can be readily produced in
sufficient quantities to administer to humans (31).
The mechanisms of cell death that occur within the initial hours of an
MI and that may depend on NF-B are not completely understood
(6, 26). Activation of NF-B has been shown to regulate
programmed cell death or apoptosis and under many experimental conditions NF-B functions to block apoptosis
(34). The degree of apoptosis detected by TUNEL
staining in our study was not significantly different between untreated
and treated hearts but was quite low (<0.01%). TUNEL staining alone
did not allow us to determine the type of cell undergoing
apoptosis, myocardial, or other. Apoptosis is felt to
occur over several hours to days, and the degree to which it
contributes to myocardial damage is controversial (1). Studies of longer duration may be required to detect a greater degree
of apoptosis in control animals (5, 13, 38).
Within the limits of our study, it appears that apoptosis is
not a major cardioprotective target of the proteasome inhibitor PS-519.
Moreover, proteasome inhibitors are not specific for inhibiting NF-B
alone, and our data leave open the possibility introduced in previously published studies that other mediators besides NF-B may be involved in the reduction of reperfusion injury observed in our study (17, 24, 25). Other possible molecular networks have been recently reviewed (28).
Another role for NF-B in promoting reperfusion injury is its
capacity to upregulate transcription of genes encoding proteins involved in the recruitment of inflammatory cells. NF-B is known to
regulate genes such as interleukin-8 and ICAM-1, which have been
demonstrated to be involved in reperfusion injury (7, 36).
It is not known whether infiltration of inflammatory cells occurred in
the 3-h reperfusion period of our experiment and whether PS-519 was
effective at blocking this mechanism. Clearly, additional studies are
needed to address these broader issues and others, including
determining the effect of PS-519 treatment beginning after the onset of
ischemia and assessing the impact of prior MI and
atherosclerotic coronary disease.
Taken together, our data and those of others support the hypothesis
that proteasome inhibition reduces reperfusion injury in multiple
organs, including the myocardium and the brain by a mechanism that
includes reduction of inducible NF-B activation. Acute treatment
with PS-519 is well tolerated in our large animal model, and its
efficacy at inhibiting proteasome function is easy to monitor in
circulating leukocytes. In a recent phase I trial in normal human
volunteers (31), PS-519 was well tolerated in 1- or 3-day
dosing regimens, inhibited 20S proteasome activity in circulating WBCs
in a dose-dependant fashion, and was shown to have an acceptable
pharmacological toxicity profile. The use of either this or other
proteasome inhibitors or NF-B inhibitors may be beneficial for
treating patients at risk for reperfusion injury during myocardial infarction.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Robin Raymer and Pam McElveen and the support staff at the Francis Owen Blood Research Laboratory, Chapel Hill, NC, for excellent care and handling of the animals.
| |
FOOTNOTES |
|---|
This work was supported by Grants 1-P20-DE-123474 and 1-P-60-DE-13079.
Address for reprint requests and other correspondence: T. C. Nichols, Depts. of Medicine and Pathology, Francis Owen Blood Research Laboratory, 350 South Old Fayetteville Rd., Univ. of North Carolina, Chapel Hill, NC 27516 (E-mail: tnichols{at}med.unc.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published November 7, 2002;10.1152/ajpheart.00851.2002
Received 23 September 2002; accepted in final form 4 November 2002.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1.
Abe, J,
Baines CP,
and
Berk BC.
Role of mitogen-activated protein kinases in ischemia and reperfusion injury: the good and the bad.
Circ Res
86:
607-609,
2000
2.
Adams, J,
Palombella VJ,
Sausville EA,
Johnson J,
Destree A,
Lazarus DD,
Maas J,
Pien CS,
Prakash S,
and
Elliott PJ.
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Cancer Res
59:
2615-2622,
1999
3.
Baldwin, AS, Jr.
The NF-kappa B and I kappa B proteins: new discoveries and insights.
Annu Rev Immunol
14:
649-683,
1996[ISI][Medline].
4.
Baldwin, AS, Jr.
Series introduction: the transcription factor NF-kappaB and human disease.
J Clin Invest
107:
3-6,
2001[ISI][Medline].
5.
Black, SC,
Huang JQ,
Rezaiefar P,
Radinovic S,
Eberhart A,
Nicholson DW,
and
Rodger IW.
Co-localization of the cysteine protease caspase-3 with apoptotic myocytes after in vivo myocardial ischemia and reperfusion in the rat.
J Mol Cell Cardiol
30:
733-742,
1998[ISI][Medline].
6.
Bolli, R,
and
Marban E.
Molecular and cellular mechanisms of myocardial stunning.
Physiol Rev
79:
609-634,
1999
7.
Boyle, EM, Jr,
Kovacich JC,
Hebert CA,
Canty TG, Jr,
Chi E,
Morgan EN,
Pohlman TH,
and
Verrier ED.
Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury.
J Thorac Cardiovasc Surg
116:
114-121,
1998
8.
Brown, PM, Jr,
Kim VB,
Boyer BJ,
Lust RM,
Chitwood WR, Jr,
and
Elbeery JR.
Regional left ventricular systolic function in humans during off-pump coronary bypass surgery.
Circulation
100:
II125-I127,
1999.
9.
Campbell, B,
Adams J,
Shin YK,
and
Lefer AM.
Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart.
J Mol Cell Cardiol
31:
467-476,
1999[ISI][Medline].
10.
Cheshire, JL,
and
Baldwin AS, Jr.
Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation.
Mol Cell Biol
17:
6746-6754,
1997[Abstract].
11.
De Sousa, E,
Veksler V,
Minajeva A,
Kaasik A,
Mateo P,
Mayoux E,
Hoerter J,
Bigard X,
Serrurier B,
and
Ventura-Clapier R.
Subcellular creatine kinase alterations. Implications in heart failure.
Circ Res
85:
68-76,
1999
12.
Dehmer, GJ,
Schmitz JM,
and
Malloy CR.
A new technique for cannulation of the coronary sinus from the femoral vein.
Cathet Cardiovasc Diagn
12:
426-429,
1986[Medline].
13.
Freude, B,
Masters TN,
Robicsek F,
Fokin A,
Kostin S,
Zimmermann R,
Ullmann C,
Lorenz-Meyer S,
and
Schaper J.
Apoptosis is initiated by myocardial ischemia and executed during reperfusion.
J Mol Cell Cardiol
32:
197-208,
2000[ISI][Medline].
14.
Fukuta, M,
Wakida Y,
Iwa T,
Uesugi M,
and
Kobayashi T.
Role of Na+-H+ exchange on reperfusion related myocardial injury and arrhythmias in an open-chest swine model.
Pacing Clin Electrophysiol
19:
2027-2033,
1996[Medline].
15.
Gao, Y,
Lecker S,
Post MJ,
Hietaranta AJ,
Li J,
Volk R,
Li M,
Sato K,
Saluja AK,
Steer ML,
Goldberg AL,
and
Simons M.
Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide.
J Clin Invest
106:
439-448,
2000[ISI][Medline].
16.
Ghosh, S,
May MJ,
and
Kopp EB.
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses.
Annu Rev Immunol
16:
225-260,
1998[ISI][Medline].
17.
Grisham, MB,
Palombella VJ,
Elliott PJ,
Conner EM,
Brand S,
Wong HL,
Pien C,
Mazzola LM,
Destree A,
Parent L,
and
Adams J.
Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome.
Methods Enzymol
300:
345-63,
1999[Medline].
18.
Haskill, S,
Beg AA,
Tompkins SM,
Morris JS,
Yurochko AD,
Sampson-Johannes A,
Mondal K,
Ralph P,
and
Baldwin AS, Jr.
Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity.
Cell
65:
1281-1289,
1991[ISI][Medline].
19.
Klein, HH,
Bohle RM,
Pich S,
Lindert-Heimberg S,
Wollenweber J,
and
Nebendahl K.
Time delay of cell death by Na+/H+-exchange inhibition in regionally ischemic, reperfused porcine hearts.
J Cardiovasc Pharmacol
30:
235-240,
1997[Medline].
20.
Klein, HH,
Bohle RM,
Pich S,
Lindert-Heimberg S,
Wollenweber J,
Schade-Brittinger C,
and
Nebendahl K.
Time-dependent protection by Na+/H+ exchange inhibition in a regionally ischemic, reperfused porcine heart preparation with low residual blood flow.
J Mol Cell Cardiol
30:
795-801,
1998[ISI][Medline].
21.
Kloner, RA,
Ganote CE,
Jennings RB,
and
Reimer KA.
Demonstration of the "no-reflow" phenomenon in the dog heart after temporary ischemia.
Recent Adv Stud Card Struct Metab
10:
463-474,
1975[Medline].
22.
Kloner, RA,
Ganote CE,
Reimer KA,
and
Jennings RB.
Distribution of coronary arterial flow in acute myocardial ischemia.
Arch Pathol
99:
86-94,
1975[Medline].
23.
Lee, R,
Nitta T,
Schmid RA,
Schuessler RB,
Harris KM,
and
Gay WA, Jr.
Retrograde infusion of lidocaine or L-arginine before reperfusion reduces myocardial infarct size.
Ann Thorac Surg
65:
1353-1359,
1998
24.
Lin, KI,
Baraban JM,
and
Ratan RR.
Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration.
Cell Death Differ
5:
577-583,
1998[ISI][Medline].
25.
Lum, RT,
Kerwar SS,
Meyer SM,
Nelson MG,
Schow SR,
Shiffman D,
Wick MM,
and
Joly A.
A new structural class of proteasome inhibitors that prevent NF-kappa B activation.
Biochem Pharmacol
55:
1391-1397,
1998[ISI][Medline].
26.
Maxwell, SR,
and
Lip GY.
Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options.
Int J Cardiol
58:
95-117,
1997[ISI][Medline].
27.
Morishita, R,
Sugimoto T,
Aoki M,
Kida I,
Tomita N,
Moriguchi A,
Maeda K,
Sawa Y,
Kaneda Y,
Higaki J,
and
Ogihara T.
In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction.
Nat Med
3:
894-899,
1997[ISI][Medline].
28.
Patterson, C,
and
Cyr D.
Welcome to the machine: a cardiologist's introduction to protein folding and degradation.
Circulation
106:
2739-2744,
2002.
29.
Ravn, HB,
Moeldrup U,
Brookes CI,
Ilkjaer LB,
White P,
Chew M,
Jensen L,
Johnsen S,
Birk-Soerensen L,
and
Hjortdal VE.
Intravenous magnesium reduces infarct size after ischemia/reperfusion injury combined with a thrombogenic lesion in the left anterior descending artery.
Arterioscler Thromb Vasc Biol
19:
569-574,
1999
30.
Schulz, R,
Post H,
Vahlhaus C,
and
Heusch G.
Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin.
Circulation
98:
1022-1029,
1998
31.
Shah IM, Lees KR, Pien CP, and Elliott PJ. Early clinical
experience with the novel proteasome inhibitor PS-519. J
Clin Pharmacol. In press.
32.
Sheppard, KA,
Rose DW,
Haque ZK,
Kurokawa R,
McInerney E,
Westin S,
Thanos D,
Rosenfeld MG,
Glass CK,
and
Collins T.
Transcriptional activation by NF-kappaB requires multiple coactivators.
Mol Cell Biol
19:
6367-6378,
1999
33.
Smits, GJ,
McVey M,
Cox BF,
Perrone MH,
and
Clark KL.
Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction.
J Pharmacol Exp Ther
286:
611-618,
1998
34.
Wang, CY,
Mayo MW,
Korneluk RG,
Goeddel DV,
and
Baldwin AS, Jr.
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science
281:
1680-1683,
1998
35.
Wikstrom, M,
Martinussen HJ,
Wikstrom G,
Ericsson A,
Nyman R,
Waldenstrom A,
and
Hemmingsson A.
MR imaging of acute myocardial infarction in pigs using Gd-DTPA-labeled dextran.
Acta Radiol
33:
301-308,
1992[Medline].
36.
Yamazaki, T,
Seko Y,
Tamatani T,
Miyasaka M,
Yagita H,
Okumura K,
Nagai R,
and
Yazaki Y.
Expression of intercellular adhesion molecule-1 in rat heart with ischemia/reperfusion and limitation of infarct size by treatment with antibodies against cell adhesion molecules.
Am J Pathol
143:
410-418,
1993[Abstract].
37.
Zandi, E,
and
Karin M.
Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex.
Mol Cell Biol
19:
4547-4551,
1999
38.
Zhao, ZQ,
Nakamura M,
Wang NP,
Wilcox JN,
Shearer S,
Ronson RS,
Guyton RA,
and
Vinten-Johansen J.
Reperfusion induces myocardial apoptotic cell death.
Cardiovasc Res
45:
651-660,
2000
This article has been cited by other articles:
|
|
 |
|
  W. E. Stansfield and C. H. Selzman Reply Ann. Thorac. Surg., April 1, 2008; 85(4): 1504 - 1504. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Huang, E. Patterson, X. Yu, M. W. Garrett, I. De Aos, and D. C. Kem Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1298 - H1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Stansfield, R.-H. Tang, N. C. Moss, A. S. Baldwin, M. S. Willis, and C. H. Selzman Proteasome inhibition promotes regression of left ventricular hypertrophy Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H645 - H650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukai Targeting Proteasome Worsens Atherosclerosis Circ. Res., October 26, 2007; 101(9): 859 - 861. [Full Text] [PDF]
|
|
|
|
|
|
N. C. Moss, W. E. Stansfield, M. S. Willis, R.-H. Tang, and C. H. Selzman IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2248 - H2253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, R. B. Marchase, and J. C. Chatham Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1391 - H1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Stansfield, N. C. Moss, M. S. Willis, R. Tang, and C. H. Selzman Proteasome Inhibition Attenuates Infarct Size and Preserves Cardiac Function in a Murine Model of Myocardial Ischemia-Reperfusion Injury Ann. Thorac. Surg., July 1, 2007; 84(1): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang and J. Robbins Heart Failure and Protein Quality Control Circ. Res., December 8, 2006; 99(12): 1315 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Gomes, C. Zong, R. D. Edmondson, X. Li, E. Stefani, J. Zhang, R. C. Jones, S. Thyparambil, G.-W. Wang, X. Qiao, et al. Mapping the Murine Cardiac 26S Proteasome Complexes Circ. Res., August 18, 2006; 99(4): 362 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Powell The ubiquitin-proteasome system in cardiac physiology and pathology Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H1 - H19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Zolk, C. Schenke, and A. Sarikas The ubiquitin-proteasome system: Focus on the heart Cardiovasc Res, June 1, 2006; 70(3): 410 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yu, S. Huang, E. Patterson, M. W. Garrett, K. M. Kaufman, J. P. Metcalf, M. Zhu, S. T. Dunn, and D. C. Kem Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1960 - H1967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Das, S. R. Powell, P. Wang, A. Divald, K. Nesaretnam, A. Tosaki, G. A. Cordis, N. Maulik, and D. K. Das Cardioprotection with palm tocotrienol: antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H361 - H367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Meiners, B. Hocher, A. Weller, M. Laule, V. Stangl, C. Guenther, M. Godes, A. Mrozikiewicz, G. Baumann, and K. Stangl Downregulation of Matrix Metalloproteinases and Collagens and Suppression of Cardiac Fibrosis by Inhibition of the Proteasome Hypertension, October 1, 2004; 44(4): 471 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Thiemermann Inhibition of the activation of nuclear factor kappa B to reduce myocardial reperfusion injury and infarct size Cardiovasc Res, July 1, 2004; 63(1): 8 - 10. [Full Text] [PDF]
|
|
|
|
|
|
Y. Onai, J.-i. Suzuki, T. Kakuta, Y. Maejima, G. Haraguchi, H. Fukasawa, S. Muto, A. Itai, and M. Isobe Inhibition of I{kappa}B phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury Cardiovasc Res, July 1, 2004; 63(1): 51 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Williams, R. Berti, J. R. Dave, P. J. Elliot, J. Adams, and F. C. Tortella Delayed Treatment of Ischemia/Reperfusion Brain Injury: Extended Therapeutic Window with the Proteosome Inhibitor MLN519 Stroke, May 1, 2004; 35(5): 1186 - 1191. [Abstract] [Full Text] [PDF]
|
|
| ||||||
